Affinage

CALCRL

Calcitonin gene-related peptide type 1 receptor · UniProt Q16602

Length
461 aa
Mass
53.0 kDa
Annotated
2026-04-28
47 papers in source corpus 23 papers cited in narrative 23 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CALCRL (calcitonin receptor-like receptor, CLR) is a class B G protein-coupled receptor whose ligand specificity is dictated by obligate heterodimerization with receptor activity-modifying proteins (RAMPs): CALCRL/RAMP1 forms the CGRP receptor, while CALCRL/RAMP2 and CALCRL/RAMP3 constitute adrenomedullin receptors, each coupling to Gαs-mediated cAMP production, G protein recruitment, and β-arrestin signaling (PMID:10781016, PMID:17503773). N-glycosylation of CALCRL at Asn123 is required for proper receptor conformation, cell-surface transport, and ligand binding (PMID:11389975), and the CALCRL promoter contains a functional HIF-1α-responsive element that upregulates expression under hypoxia (PMID:12824306). In the vasculature, CALCRL mediates vasodilation, endothelial angiogenesis, eNOS activation, and retinal ganglion cell survival through RAMP-dependent signaling (PMID:27940069, PMID:14712479, PMID:38602103, PMID:31000793); in hematopoiesis, the CGRP–CALCRL/RAMP1 axis supports stress-induced hematopoietic stem cell function (PMID:30674976), while in acute myeloid leukemia the ADM–CALCRL axis drives leukemic stem cell maintenance, cell cycle progression, DNA repair, OxPHOS, and chemotherapy resistance through E2F1/BCL2- and XRCC5/AKT-dependent pathways (PMID:33462236, PMID:37948318).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1999 High

    Establishing that CALCRL requires a RAMP co-receptor for ligand recognition resolved how a single orphan GPCR could serve as both a CGRP and an adrenomedullin receptor depending on its RAMP partner.

    Evidence Co-transfection of RAMP2/CRLR in HeLa and HEK293 cells showing cAMP response to adrenomedullin; extended by HEK293 co-expression with RAMP1/2/3 demonstrating CGRP vs. AM selectivity

    PMID:10217420 PMID:10781016

    Open questions at the time
    • Structural basis of RAMP-determined ligand selectivity was not yet resolved
    • Stoichiometry of the CALCRL-RAMP complex at the cell surface was unknown
  2. 2001 High

    Site-directed mutagenesis identified Asn123 N-glycosylation as essential for CALCRL ligand binding and surface transport, demonstrating that post-translational modification — not just RAMP identity — governs receptor competence.

    Evidence Mutagenesis of N-glycosylation sites combined with radioligand binding and FACS in HEK293 and CHO-K1 cells; antisense knockdown in cardiomyocytes confirming CRLR is essential for AM signaling

    PMID:11389975 PMID:11754972 PMID:11854283

    Open questions at the time
    • Contribution of individual RAMP glycosylation sites to heterodimer stability was not yet tested
    • Whether glycosylation defects affect RAMP-specific pharmacology was unresolved
  3. 2003 High

    Discovery of HIF-1α-dependent transcriptional regulation of CALCRL through a promoter HRE connected the receptor to hypoxia-responsive gene programs, explaining its upregulation in ischemic tissues.

    Evidence Promoter cloning, HRE mutagenesis, and reporter assays in primary microvascular endothelial cells; RAMP3 mutagenesis in Xenopus oocytes confirming conserved cysteines are required for AM binding

    PMID:12824306 PMID:12939163

    Open questions at the time
    • Whether hypoxia-induced CALCRL upregulation alters RAMP stoichiometry and thus ligand selectivity in vivo was untested
    • Post-transcriptional regulation of CALCRL protein under acute hypoxia was not yet characterized
  4. 2005 Medium

    Functional studies extended CALCRL biology into cardioprotection and post-transcriptional regulation, showing CGRP–CALCRL/RAMP1 signaling protects cardiomyoblasts from apoptosis and that acute hypoxia increases CALCRL protein without mRNA changes.

    Evidence Apoptosis assays with CGRP(8-37) blockade in H9c2 cells; Western blot vs. RT-PCR under acute hypoxia in coronary artery smooth muscle cells and chronic hypoxia rat model

    PMID:15567147 PMID:16242145

    Open questions at the time
    • Mechanism of post-transcriptional CALCRL stabilization under acute hypoxia was not identified
    • Downstream effectors of CGRP-mediated anti-apoptosis beyond Bcl-2/Bax were unknown
  5. 2007 High

    BRET-based biophysical studies demonstrated that CALCRL and RAMP1 form selective heterodimers (not random oligomers) and that G protein and β-arrestin recruitment require the intact heterodimer, establishing the quaternary signaling unit.

    Evidence BRET titration assays with CRLR-Rluc and RAMP1-GFP fusions in living cells combined with cAMP and radioligand binding

    PMID:17503773

    Open questions at the time
    • Whether CALCRL homodimers have independent signaling capacity was untested
    • Structural basis of heterodimer selectivity was unknown at atomic resolution
  6. 2016 High

    Genetic epistasis in RAMP and Calcrl knockout mice resolved the in vivo receptor pharmacology of vasodepressor responses, showing AM hypotension acts primarily through CLR/RAMP1 with contributions from CLR/RAMP2 and CLR/RAMP3.

    Evidence Blood pressure measurement in Ramp1−/−, Ramp2+/−, Ramp3−/−, double-KO, and Calcrl+/− mice with intravenous ligand injection

    PMID:27940069

    Open questions at the time
    • Tissue-specific RAMP expression patterns driving organ-level AM vs. CGRP responses were not mapped
    • Whether compensatory RAMP switching occurs in single-RAMP knockout animals was unresolved
  7. 2019 Medium

    Multiple studies converged to establish CALCRL as a functional dependency in AML and a regulator of normal hematopoietic stem cells: CRISPR knockout impaired leukemic colony formation, CGRP antagonism reduced leukemic burden, RAMP1 deficiency compromised stress hematopoiesis, and RAMP2 haploinsufficiency caused retinal ganglion cell death.

    Evidence CRISPR-Cas9 KO in AML lines; olcegepant antagonism in mouse AML model; Ramp1−/− BM transplantation and ROS/apoptosis assays; Ramp2+/− mouse retinal phenotyping

    PMID:30674976 PMID:31000793 PMID:31182782 PMID:31756985

    Open questions at the time
    • Whether CALCRL dependency in AML is ligand-driven or constitutive was unclear
    • The relative contribution of CGRP vs. AM signaling arms to leukemic stem cell maintenance was unresolved
    • Retinal phenotype confirmation in CALCRL-specific conditional knockouts was lacking
  8. 2020 High

    Crystal structure of erenumab bound to the CGRP receptor revealed that the antibody's CDR-H3 loop inserts into the CLR–RAMP1 interface, providing the first atomic-resolution view of the ligand-binding site and validating the heterodimer interface as a druggable target.

    Evidence Crystal structure of erenumab-CGRPR complex

    PMID:32049005

    Open questions at the time
    • Full-length active-state structure of CALCRL/RAMP1 with CGRP peptide and G protein was not yet determined
    • Structural basis of RAMP2/3-dependent AM selectivity remained unresolved
  9. 2021 High

    Mechanistic dissection in patient-derived xenograft models showed the ADM–CALCRL axis drives leukemic stem cell maintenance via E2F1/BCL2-dependent cell cycle progression, DNA repair, and mitochondrial OxPHOS, positioning CALCRL as a chemoresistance node.

    Evidence CALCRL knockdown in PDX models with cell cycle, DNA repair, OxPHOS, and LSC frequency assays post-cytarabine

    PMID:33462236

    Open questions at the time
    • Direct transcriptional targets of CALCRL-E2F1 axis in LSCs were not comprehensively mapped
    • Whether CALCRL inhibition synergizes with BCL2 inhibitors (venetoclax) was untested
  10. 2023 Medium

    CALCRL overexpression was shown to confer daunorubicin resistance through XRCC5 upregulation and AKT/PKCε phosphorylation, with XRCC5 knockdown restoring drug sensitivity — identifying a specific DNA repair effector downstream of CALCRL.

    Evidence CALCRL overexpression and XRCC5 siRNA rescue in HL-60 and Molm-13 cells; nude mouse xenograft model

    PMID:37948318

    Open questions at the time
    • Whether CALCRL regulates XRCC5 transcriptionally or post-transcriptionally was not determined
    • Generalizability to non-AML cancers was untested
  11. 2024 High

    Identification of an HSF1-bound shear stress-responsive enhancer at rs880890 controlling CALCRL expression in endothelial cells connected the receptor to flow-dependent vascular homeostasis and downstream eNOS/NO signaling.

    Evidence CRISPR enhancer deletion, siRNA knockdown, ATAC-seq, ChIP-qPCR, functional assays in human aortic endothelial cells

    PMID:38602103

    Open questions at the time
    • In vivo validation of the enhancer's contribution to CALCRL expression in shear-exposed vasculature was not performed
    • Whether this enhancer operates in non-endothelial CALCRL-expressing cell types is unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the structural basis of RAMP2/3-dependent adrenomedullin selectivity at atomic resolution, whether CALCRL signals constitutively in the absence of ligand in disease contexts such as AML, and the therapeutic window for CALCRL inhibition given its dual roles in normal hematopoiesis and leukemic stem cell survival.
  • No full active-state structure of CALCRL/RAMP2 or CALCRL/RAMP3 with G protein
  • Ligand-independent vs. ligand-dependent CALCRL activity in AML not discriminated
  • Conditional CALCRL knockout models in adult hematopoietic system not reported

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0060090 molecular adaptor activity 2
Localization
GO:0005886 plasma membrane 4
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-1643685 Disease 4 R-HSA-1266738 Developmental Biology 2 R-HSA-109582 Hemostasis 1
Partners
HIF1AHSF1RAMP1RAMP2RAMP3XRCC5
Complex memberships
CLR/RAMP1 (CGRP receptor)CLR/RAMP2 (AM1 receptor)CLR/RAMP3 (AM2 receptor)

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 The RAMP2/CRLR (CALCRL) complex functions as a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells, mediating cAMP elevation upon adrenomedullin stimulation. Co-transfection of RAMP2 and CRLR in HeLa EBNA and 293 EBNA cells with cAMP functional assay FEBS letters High 10217420
2000 Rat CRLR forms a CGRP receptor when co-expressed with RAMP1, and an adrenomedullin receptor when co-expressed with RAMP2 or RAMP3, establishing RAMP identity as the determinant of ligand specificity for CALCRL. Co-transfection in HEK293 cells with radioligand binding and cAMP functional assays; correlation of RAMP mRNA with binding in rat tissues British journal of pharmacology High 10781016
2002 CRLR cell-surface expression does not require heterodimer assembly with RAMPs; RAMP2 and RAMP3 reach the plasma membrane via N-glycosylation-dependent mechanisms, while RAMP1 (non-glycosylated) requires heterodimerization with CRLR for plasma membrane targeting. Xenopus oocyte expression system with quantitative cell-surface binding assay; N-glycosylation site mutagenesis of RAMP1 The Journal of biological chemistry High 11854283
2001 Glycosylation of CRLR at Asn123 is required for ligand binding and signal transduction; loss of glycosylation at this site impairs cell-surface transport and receptor conformation without affecting expression of N66Q or N118Q mutants. Site-directed mutagenesis of N-glycosylation sites, radioligand binding, FACS analysis in HEK293 EBNA and CHO-K1 cells Biochimica et biophysica acta High 11389975
2003 N-glycosylation and conserved cysteine residues in RAMP3 are critical for functional expression of the CRLR/RAMP3 adrenomedullin receptor; elimination of all N-glycans reduces AM binding, and mutation of all six cysteines abolishes adrenomedullin binding. Xenopus oocyte expression system with [125I]AM radioligand binding, N-glycosylation site and cysteine mutagenesis Biochemistry High 12939163
2007 CRLR and RAMP1 form selective heterodimers at the cell surface (not random oligomers); both CRLR and RAMP1 can also form homodimers. CRLR recruits G proteins and β-arrestin upon CGRP stimulation only in the presence of RAMP1. BRET titration assays in living cells; radioligand binding; cAMP production assays with CRLR-Rluc and RAMP1-GFP fusion proteins Biochemistry High 17503773
2001 Adrenomedullin signaling in rat cardiomyocytes requires CRLR and RAMP2 to constitute functional AM receptors; overexpression of CRLR or RAMP2 potentiates AM-induced CRE-luciferase (cAMP) signaling, and CRLR antisense abolishes AM response. Transient transfection of cardiomyocytes with CRE-luciferase reporter; CRLR antisense and receptor antagonist CGRP(8-37) blockade Peptides High 11754972
2003 The human CRLR gene promoter contains a functional hypoxia-response element (HRE) that is activated by HIF-1α under hypoxia; site-directed mutagenesis of the HRE abolishes hypoxia-induced promoter activity in primary microvascular endothelial cells. 5'-RACE, promoter cloning, reporter gene assays, site-directed mutagenesis of HRE, semi-quantitative RT-PCR under hypoxic conditions FASEB journal High 12824306
2004 CRLR/RAMP2 and CRLR/RAMP3 receptors mediate adrenomedullin-induced HUVEC migration, invasion, and differentiation into cord-like structures during angiogenesis; AM acts independently of VEGF in capillary tube formation. HUVEC migration and invasion assays, Matrigel differentiation assay, blocking antibodies and receptor-specific pharmacology International journal of cancer Medium 14712479
2005 CGRP exerts antiapoptotic effects in H9c2 cardiomyoblasts specifically through the RAMP1/CRLR complex, as shown by CGRP(8-37) antagonist blockade; RAMP1 expression is upregulated by CGRP and CGRP prevents oxidative stress-induced Bcl-2 decrease and Bax increase. MTT assays, caspase-3 activation, DNA fragmentation, RT-PCR, dot blot; CGRP(8-37) antagonist and adrenomedullin comparison in H9c2 cells Journal of molecular and cellular cardiology Medium 16242145
2020 Crystal structure of erenumab (anti-CGRPR monoclonal antibody) in complex with CGRPR reveals that erenumab's 21-residue CDR-H3 loop projects into the interface between CLR (CALCRL) and RAMP1, directly blocking ligand binding by contacting residues specific to both CLR and RAMP1. Crystal structure determination of erenumab-CGRPR complex Cell reports High 32049005
2016 The hypotensive response to adrenomedullin is primarily mediated through CLR/RAMP1, with contributions from CLR/RAMP2 and CLR/RAMP3; CGRP hypotension is predominantly through CLR/RAMP1. Genetic reduction of Calcrl attenuates the hypotensive response to both AM and CGRP in vivo. Blood pressure measurement in Ramp1-/-, Ramp2+/-, Ramp3-/-, Ramp1-/-/Ramp3-/- double-KO, and Calcrl+/- mice with intravenous AM and CGRP injection Peptides High 27940069
2019 CALCRL knockdown by CRISPR-Cas9 significantly impairs colony formation in human myeloid leukemia cell lines, establishing a functional role for CALCRL in leukemic cell growth. CRISPR-Cas9 knockout in human AML cell lines with colony formation assay Leukemia Medium 31182782
2019 The CGRP-CALCRL/RAMP1 axis protects AML cells from chemotherapy-induced apoptosis; CGRP antagonist olcegepant increases differentiation, reduces leukemic burden, and decreases stem cell properties in a mouse AML model. Apoptosis assays in AML cell lines and primary samples; CGRP antagonist (olcegepant) treatment; C57BL/6 mouse AML model with in vivo leukemic burden and stem cell assays International journal of molecular sciences Medium 31756985
2021 The ADM-CALCRL axis drives cell cycle progression, DNA repair, and mitochondrial OxPHOS function in AML blasts dependent on E2F1 and BCL2; CALCRL knockdown decreases leukemic stem cell frequency and sensitizes to cytarabine in patient-derived xenograft models. CALCRL knockdown in patient-derived xenograft models; cell cycle, DNA repair, and OxPHOS functional assays; in vivo LSC frequency assays post-chemotherapy Nature communications High 33462236
2019 CGRP-CALCRL/RAMP1 signaling is required for stress-induced hematopoiesis; Ramp1-deficient mice show decreased bone marrow repopulation capacity, reduced proliferation, enhanced ROS production, and increased apoptosis under proliferative stress. Ramp1-/- mouse model; BM transplantation/repopulation assay; ROS measurement; apoptosis assay; CGRP administration experiments Scientific reports Medium 30674976
2019 Mutant RAMP2 proteins aggregate in transfected cells and disrupt AM-RAMP2/CRLR-cAMP signaling; ablation of one Ramp2 allele leads to cAMP reduction and retinal ganglion cell death in mice, establishing that the RAMP2/CRLR-cAMP axis is essential for retinal ganglion cell survival. Heterozygous Ramp2 knockout mouse model; transfection of mutant RAMP2 constructs; cAMP measurement; retinal ganglion cell death assay Genetics in medicine Medium 31000793
2005 Acute hypoxia in coronary artery smooth muscle cells induces a rapid increase in CRLR protein independently of changes in CRLR mRNA, indicating a post-transcriptional regulatory mechanism; chronic hypoxia in rats enhances both mRNA and protein of CRLR and all three RAMPs in cardiac ventricles. Western blotting and RT-PCR in human coronary artery smooth muscle cells under acute hypoxia; chronic hypobaric hypoxia rat model Biochemical and biophysical research communications Medium 15567147
2024 CALCRL expression in endothelial cells is regulated by an HSF1-bound shear stress-responsive enhancer at rs880890; CRISPR deletion of this enhancer downregulates CALCRL expression, and CALCRL knockdown reduces eNOS, apelin, angiopoietin, prostaglandin, and EDN1 signaling, decreasing cell proliferation, tube formation, and NO production. CRISPR enhancer deletion, siRNA knockdown, ATAC-seq, ChIP-qPCR, electromobility shift assay, luciferase reporter assay, functional proliferation and tube formation assays in human aortic endothelial cells Arteriosclerosis, thrombosis, and vascular biology High 38602103
2023 CALCRL overexpression in AML cells confers resistance to daunorubicin through upregulation of XRCC5 and PDK1, leading to increased AKT/PKCε phosphorylation; XRCC5 siRNA in CALCRL-overexpressing cells restores drug sensitivity and increases apoptosis. CALCRL overexpression constructs in HL-60 and Molm-13 cells; RT-PCR, Western blot; XRCC5 siRNA rescue experiment; nude mouse xenograft model Anti-cancer drugs Medium 37948318
2024 Spinal Calcrl+ neurons function as projection neurons that amplify mechanical itch signaling; chemogenetic activation induces mechanical itch sensitization, chemogenetic inhibition alleviates it in chronic itch models, and chronic itch enhances intrinsic excitability and Aβ-fiber-evoked excitatory synaptic input to Calcrl+ neurons with reduced inhibitory input. Chemogenetic (DREADD) manipulation, behavioral tests, electrophysiology, morphological assays in chronic itch mouse models PloS one Medium 41248150
2025 CALCRL (as core component of the CGRP receptor) is upregulated in AD hippocampus; pharmacological blockade with rimegepant reduces Aβ1-42 oligomer-induced neuronal death and glial inflammation via HDAC11 inhibition, which enhances LXRβ acetylation and ABCA1 expression, reprogramming neuronal lipid metabolism. 5×FAD mouse model; Calca knockout; rimegepant pharmacological blockade; HDAC11/LXRβ/ABCA1 mechanistic pathway analysis; neurobehavioral and neuropathological assays bioRxivpreprint Low bio_10.1101_2025.10.17.683079
2025 De novo designed miniprotein antagonists bind CGRPR (CLR/CALCRL + RAMP1) with high affinity; cryo-EM structures confirm atomic-level agreement between designed and experimentally determined structures, establishing precise conformational control of receptor function. Computational de novo protein design; cryo-electron microscopy structure determination; high-throughput receptor diversion microscopy screen bioRxivpreprint Medium bio_10.1101_2025.03.23.644666

Source papers

Stage 0 corpus · 47 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells. FEBS letters 113 10217420
2000 CGRP and adrenomedullin binding correlates with transcript levels for calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) in rat tissues. British journal of pharmacology 112 10781016
2004 Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. International journal of cancer 110 14712479
2003 Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 66 12824306
2002 Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. British journal of pharmacology 64 12086988
2021 Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Nature communications 53 33462236
2005 Antiapoptotic effect of calcitonin gene-related peptide on oxidative stress-induced injury in H9c2 cardiomyocytes via the RAMP1/CRLR complex. Journal of molecular and cellular cardiology 51 16242145
2002 Respective roles of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMP) in cell surface expression of CRLR/RAMP heterodimeric receptors. The Journal of biological chemistry 48 11854283
2020 Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab). Cell reports 43 32049005
2000 Dexamethasone increases RAMP1 and CRLR mRNA expressions in human vascular smooth muscle cells. Biochemical and biophysical research communications 40 10772950
2007 Assembly and signaling of CRLR and RAMP1 complexes assessed by BRET. Biochemistry 38 17503773
2019 The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia 37 31182782
2004 RAMPs and CRLR expressions in osteoblastic cells after dexamethasone treatment. Biochemical and biophysical research communications 33 15358098
2001 Immunohistochemical detection of calcitonin gene-related peptide receptor (CGRPR)-1 in the endothelium of human coronary artery and bronchial blood vessels. Neuropeptides 29 11346311
2001 Adrenomedullin signalling in cardiomyocytes is dependent upon CRLR and RAMP2 expression. Peptides 28 11754972
2001 Glycosylation of human CRLR at Asn123 is required for ligand binding and signaling. Biochimica et biophysica acta 26 11389975
2003 Evidence for the existence of a new receptor for CGRP, which is not CRLR. Peptides 24 12576086
2019 CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia. International journal of molecular sciences 23 31756985
2003 N-Glycosylation and conserved cysteine residues in RAMP3 play a critical role for the functional expression of CRLR/RAMP3 adrenomedullin receptor. Biochemistry 23 12939163
2001 Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells. Molecular and cellular biochemistry 23 11693189
2019 Mutant RAMP2 causes primary open-angle glaucoma via the CRLR-cAMP axis. Genetics in medicine : official journal of the American College of Medical Genetics 19 31000793
2017 The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 18 29124668
2021 Calcitonin receptor-like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML. Blood advances 15 34559198
2019 CGRP-CRLR/RAMP1 signal is important for stress-induced hematopoiesis. Scientific reports 15 30674976
2009 Investigation of the association between CALCRL polymorphisms and primary angle closure glaucoma. Molecular vision 15 19898635
2005 Post-transcriptional regulation of CRLR expression during hypoxia. Biochemical and biophysical research communications 15 15567147
2004 The immunohistochemical expression of calcitonin receptor-like receptor (CRLR) in human gliomas. Journal of clinical pathology 15 14747444
2021 To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations. ACS chemical neuroscience 13 34184869
2016 Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice. Peptides 13 27940069
2006 Two novel cell specific receptor proteins, CRLR and CD 117 in human glial tumors. Clinical neuropathology 10 16719406
2001 Phenotypic changes of adrenomedullin receptor components, RAMP2, and CRLR mRNA expression in cultured rat vascular smooth muscle cells. Biochemical and biophysical research communications 9 11676473
2021 Molecular simulations reveal the impact of RAMP1 on ligand binding and dynamics of calcitonin gene-related peptide receptor (CGRPR) heterodimer. Computers in biology and medicine 7 34923287
1999 Equipotent in vitro actions of alpha- and beta-CGRP on guinea pig basilar artery are likely to be mediated via CRLR derived CGRP receptors. Regulatory peptides 7 10651059
2023 Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues. International journal of molecular sciences 6 36835377
2024 CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations. Drug development research 4 38349260
2024 Coronary Artery Disease Risk Variant Dampens the Expression of CALCRL by Reducing HSF Binding to Shear Stress Responsive Enhancer in Endothelial Cells In Vitro. Arteriosclerosis, thrombosis, and vascular biology 3 38602103
2022 Virtual drug repurposing study for the CGRPR identifies pentagastrin and leuprorelin as putative candidates. Journal of molecular graphics & modelling 3 35803082
2020 Calcitonin gene-related peptide receptor Calcrl is enriched in hair follicles stem cells and differentially expressed in interfollicular epidermis in murine skin. Neuroreport 3 32576770
2023 CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway. Anti-cancer drugs 2 37948318
2021 Short tandem repeat near hypoxia response element (HRE) instead of HRE genetic variants in promoter calcitonin receptor-like receptor (CRLR) gene as risk factor in severe preeclampsia: a preliminary study. BMC research notes 2 33413630
2025 miR-101-3p overexpression suppresses NSCLC progression through Immune-Related gene CALCRL regulation and lncRNA NEAT1 axis. Molecular biology reports 1 40974392
2024 Calcitonin gene‑related peptide alleviates hyperoxia‑induced human alveolar cell injury via the CGRPR/TRPV1/Ca2+ axis. Molecular medicine reports 1 38695251
2024 Spinal RAMP1-mediated neuropathic pain sensitisation in the aged mice through the modulation of CGRP-CRLR pain signalling. Heliyon 1 39224276
2026 Identification of the key immune and inflammatory related gene CALCRL as diagnostic biomarker in differentiating uterine leiomyosarcoma from leiomyoma. Frontiers in cell and developmental biology 0 42039143
2025 [Migraine patients treated with CGRP(R) antibodies : Are they different from patients treated with nonspecific oral prophylaxis? Analysis from the DMKG headache registry]. Schmerz (Berlin, Germany) 0 40932510
2025 Spinal Calcrl+ neurons amplify mechanical itch signaling via synaptic plasticity in chronic itch model. PloS one 0 41248150
2025 Hyperglycemia Increased The Expression of CALCRL G Protein-Coupled Receptor in Monocytes from Diabetic Patients. Cell journal 0 41420470